Biogen Idec and Isis Pharmaceuticals Sign Second Rare Disease Option Agreement
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 7 (Table of Contents)
Published: 10 Jul-2012
DOI: 10.3833/pdr.v2012.i7.1765 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Isis Pharmaceuticals has collaborated with Biogen Idec for a second time for the development and commercialisation of an antisense drug candidate for the rare genetic neuromuscular disease myotonic dystrophy type 1 (DM1)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS